Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Somatostatin

Alternative Names: somatostatin
Latest Update: 2025-05-15
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: SSTR Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Czech | Ecuador | Egypt | France | Germany | Greece | Hong Kong | India | Indonesia | Italy | Jordan | Korea | Luxembourg | Malta | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Switzerland | Taiwan | Turkey | United Arab Emirates | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

05/15/2025

News Article

 Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025

05/13/2025

News Article

 Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

05/01/2025

News Article

 Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing

04/25/2025

News Article

 CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions